[Evaluation of megestrol acetate as monotherapy in disseminated prostatic carcinoma].
To determine the effects of megestrol acetate on testosterone, dehydroepiandrosterone and PSA levels in patients with disseminated prostatic carcinoma. 26 patients with disseminated prostatic carcinoma treated with megestrol acetate were followed for 21 months to determine its effects on testosterone, dehydroepiandrosterone and PSA levels. We observed a testicular and adrenal antiandrogenic effect. Patient clinical course improved when PSA levels dropped, although this improvement was not related with changes in androgen levels.